Biogen Inc. / Human Immunology Biosciences

IgA Nephropathy / Kidney Transplant AMR

10K US cases/yr · $6.0B Global Nephrology Biologics (2028E)

Disease Overview

Felzartamab (anti-CD38) depletes pathogenic plasma cells. FDA BTD for kidney transplant AMR. Phase 2 IGNAZ: ~50% UPCR reduction in IgAN maintained 18+ months post-dosing. Three Phase 3 programs in 2025.

Competitive Landscape

Competing with povetacicept (Vertex), Filsuvez (Travere), iptacopan (Novartis) in IgAN. Anti-CD38 targeting plasma cells is differentiated. No approved targeted therapies for transplant AMR.

Kidney Transplant AMR

Competitive Landscape

Felzartamab is an anti-CD38 monoclonal antibody for late/chronic antibody-mediated rejection (AMR) in kidney transplant, a disease with no FDA-approved therapy — the competitive set is almost entirely off-label. Anti-CD38 (direct MOA competitors): daratumumab (Darzalex, J&J) is approved in multiple myeloma and used off-label in AMR case series; isatuximab (Sarclisa, Sanofi) is similarly off-label in select centers. Plasma cell/B-cell depletion: rituximab (Rituxan, Roche/biosimilars) is the most widely used off-label agent for AMR; bortezomib (Velcade, Takeda/generic) is a proteasome inhibitor used off-label to deplete plasma cells. Complement inhibitors: eculizumab (Soliris, AstraZeneca/Alexion) and ravulizumab (Ultomiris, AstraZeneca/Alexion) are approved in PNH/aHUS and used off-label in complement-mediated AMR; Soliris generated approximately $1.8B in 2023 AstraZeneca revenues. Pipeline/emerging: imlifidase (Idefirix, Hansa Biopharma) is EMA-approved (conditional) for kidney transplant desensitization via IgG cleavage but not FDA-approved; its role is pre-transplant, distinct from chronic AMR. Tocilizumab (Actemra, Roche) is used off-label for subclinical/chronic AMR based on small studies. The Phase 2 felzartamab data published in NEJM 2024 (Mayer et al.) demonstrated morphologic AMR resolution versus placebo — a first-in-class signal. Felzartamab's commercial path depends on Phase 3 confirmation and registration as the first AMR-approved agent, where pricing anchors to orphan transplant biologics like Soliris.

Primary Membranous Nephropathy

Competitive Landscape

Felzartamab (anti-CD38 mAb) targets primary membranous nephropathy (PMN), a rare autoimmune glomerular disease driven predominantly by PLA2R autoantibodies. No drug is FDA-approved specifically for PMN — the competitive landscape is off-label, with treatment selection driven by KDIGO 2021 guidelines. Anti-CD20 B-cell depletion (de facto standard): rituximab (Rituxan, Roche/biosimilars) is the most widely used agent and was shown non-inferior to cyclosporine in the MENTOR trial (Fervenza et al., NEJM 2019); obinutuzumab (Gazyva, Roche) has investigator-led evidence in rituximab-refractory PMN. Alkylating agent + steroid (modified Ponticelli regimen): cyclophosphamide (Cytoxan, BMS/generic) plus corticosteroids remains guideline-recommended for high-risk disease. Calcineurin inhibitors: cyclosporine (Sandimmune/Neoral, Novartis/generic) and tacrolimus (Prograf, Astellas/generic) are alternatives but with high relapse rates. Anti-CD38 (direct MOA class): felzartamab's Phase 2 M-PLACE and NewPLACE trials demonstrated anti-PLA2R antibody depletion and immunologic/clinical remission — the first CD38-targeted data in PMN. Emerging: MOR202 (a separate anti-CD38, now MorphoSys/Incyte) has preliminary nephrology data; anti-CD19 CAR-T is in early exploration for refractory cases. Felzartamab's commercial opportunity hinges on Phase 3 success and an FDA label as the first approved PMN therapy, where orphan pricing would displace off-label rituximab biosimilars in PLA2R-positive high-risk patients.

Lupus Nephritis

Competitive Landscape

Felzartamab (anti-CD38 mAb) targets lupus nephritis (LN) — a market where approvals have accelerated since 2020 but where refractory patients remain a large unmet-need pool. Calcineurin inhibitors: voclosporin (Lupkynis, Aurinia Pharmaceuticals) received FDA approval January 2021 for active LN in combination with mycophenolate/steroids; Aurinia reported Lupkynis 2023 net product revenue of approximately $158M. B-cell depletion/cytokine modulation: belimumab (Benlysta, GSK) is anti-BLyS/BAFF, FDA-approved for active LN (December 2020) plus SLE, generating approximately £1.37B in 2023 GSK sales across SLE/LN. Rituximab (Rituxan, Roche/biosimilars) is used off-label in refractory LN. Type I interferon receptor: anifrolumab (Saphnelo, AstraZeneca) is FDA-approved for SLE and under Phase 3 evaluation in LN. Anti-CD38 (direct MOA threat/comparator pool): daratumumab (Darzalex, J&J) is in early-phase refractory LN/SLE investigator-initiated trials but not approved. CAR-T (emerging franchise threat): CD19 CAR-T (autologous, multiple sponsors including Novartis, Bristol-Myers Squibb via Century, Kyverna) has produced striking drug-free remission data in refractory LN/SLE per Mackensen et al. Nature Medicine 2022. Obinutuzumab (Gazyva, Roche) Phase 3 REGENCY met primary endpoint in LN in 2024, positioning for potential approval. Felzartamab must demonstrate differentiation versus voclosporin + belimumab combination in frontline active LN or position in refractory post-biologic failure.